NLRP3 inflammasome

Overview

The NLRP3 inflammasome is a multiprotein innate immune signaling complex centered on the NOD-like receptor family pyrin domain containing 3 (NLRP3) sensor protein. It is a key regulator of inflammatory responses because, once activated by diverse cellular stress signals, it promotes assembly of the inflammasome complex, activation of caspase-1, and downstream maturation of pro-inflammatory cytokines such as interleukin-1β, as well as cleavage of Gasdermin D, which contributes to pyroptotic cell death. Because of this central role, NLRP3 inflammasome activation is widely studied in sterile inflammation, metabolic disease, neuroinflammation, fibrosis, and tissue injury.

Biologically, NLRP3 is notable for integrating signals associated with mitochondrial dysfunction, reactive oxygen species, mtDNA release, lysosomal stress, and upstream inflammatory pathways such as NF-κB, TLR2/TLR4, and MyD88-dependent signaling. In recent biomedical research, it has been investigated both as a mechanistic node in disease progression and as a therapeutic target for anti-inflammatory interventions, including small molecules, natural products, exosome-mediated effects, and pathway-directed strategies.

Focus of Latest Publications

Recent studies have established NLRP3 inflammasome as a central mediator of pathology across diverse disease contexts. Research examined NLRP3 activation in diabetic complications (diabetic kidney disease and diabetic cognitive impairment), neurodegenerative conditions (Alzheimer's disease and Parkinson's disease), acute CNS injuries (traumatic brain injury), metabolic disorders (obesity and type 2 diabetes), inflammatory diseases (gouty arthritis, acute pancreatitis, and radiation pneumonitis), cancer-related complications (cisplatin nephrotoxicity), and ocular diseases (glaucoma and alkali burn injury). Mechanistically, these studies revealed that NLRP3 inflammasome activation drives pathological inflammation through assembly of NLRP3, apoptosis-associated speck protein (ASC), and caspase-1, culminating in secretion of pro-inflammatory cytokines including interleukin-1β and interleukin-18. Common upstream triggers identified included oxidative stress, mitochondrial dysfunction, elevated nuclear factor kappa B signaling, and dysregulated microglial and macrophage activation.

Inhibition of NLRP3 inflammasome emerged as a unifying therapeutic strategy. Multiple complementary mechanisms converged on NLRP3 suppression: reducing reactive oxygen species and oxidative stress, preventing mitochondrial DNA release, suppressing nuclear factor kappa B pathway activation, promoting mitochondrial autophagy, and rebalancing macrophage and microglial polarization toward anti-inflammatory phenotypes. Pharmacological approaches included direct NLRP3 inhibitors (MCC950) and small-molecule inhibitors targeting upstream pathways. Natural compounds and nutraceuticals—quercetin, protocatechuic acid, trans-anethole, ginsenoside Rg3, and sulforaphane—suppressed NLRP3 activation through antioxidative and anti-inflammatory mechanisms. Existing therapeutics were redirected; irbesartan, an angiotensin II receptor blocker, inhibited NLRP3 inflammasome activation in diabetic kidney disease models, while ginsenoside Rg3 enhanced cisplatin efficacy while mitigating chemotherapy-induced nephrotoxicity.

Biological and cellular approaches similarly targeted NLRP3 inflammasome activity. Probiotic modulation using Akkermansia muciniphila reduced NLRP3 activation and improved cognitive outcomes in diabetic mice. mesenchymal stem cell therapies—including bone marrow-derived stem cells, umbilical cord stem cells, and engineered extracellular vesicles loaded with anti-inflammatory microRNAs—inhibited NLRP3 inflammasome through immunomodulatory mechanisms. Engineered nanoparticles combining antioxidative scaffolds (glutathione-conjugated gold nanoparticles, cerium-luteolin coordination complexes) suppressed NLRP3-mediated inflammation. Neuropeptide interventions, including oxytocin and electroacupuncture effects modulating circadian-immune coupling, engaged NLRP3 suppression through microglial phenotype switching.

Across all interventions, successful NLRP3 inhibition consistently reduced pro-inflammatory cytokines (interleukin-1β, interleukin-6, tumor necrosis factor-α), decreased microglial and macrophage activation markers, restored synaptic protein expression, and improved functional recovery in animal disease models. Combination approaches demonstrated that NLRP3 inhibition could enhance existing therapeutic benefit while reducing collateral toxicity. These converging findings across preclinical models position NLRP3 inflammasome as a high-priority therapeutic target, with diverse therapeutic modalities—from small molecules to cellular biologics—demonstrating pathway tractability in metabolic, neurodegenerative, inflammatory, and Malignant Disease contexts.

Key Publications

• NEWJun Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. (Molecular medicine reports, 2026, PMID 42318962): "High glucose stimulation upregulated the expression of NLRP3 in HK‐2 cells and promoted the expression of EMT‐associated factors."
• NEWJun Akkermansia muciniphila alleviates diabetic cognitive impairment by inhibiting NLRP3 inflammasome activation and ameliorating hippocampal synaptic defects. (Food & function, 2026, PMID 42300325): "Emerging evidence suggests that nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation contributes to diabetic cognitive impairment (DCI), making its inhibition a potential therapeutic strategy for DCI."
• NEWJun Coordination-driven self-assembly of antioxidative and anti-inflammatory cerium-luteolin nanoparticles for effective treatment of ocular alkali burns. (Journal of materials chemistry. B, 2026, PMID 42301120): "CEL NPs also suppress inflammatory responses by inhibiting the NF-κB pathway while activating the Nrf2/HO-1 axis."
• NEWJun Aging reprograms microglia toward an inflammasome-linked response to traumatic brain injury. (The Journal of clinical investigation, 2026, PMID 42294901): "Microglia-targeted perturbation of NLRP3 and ELF1 each shifted the balance and improved survival in mouse models of TBI, and the repurposed drug Imeglimin improved outcomes in these models, confirming that this pathway is druggable."
• NEWJun Pt(IV) Complexes Incorporating CDC25A/NF-κB Dual Inhibitory 1,4-Naphthoquinone Derivatives Trigger Multimodal Cell Death in A2780 Ovarian Cancer Cells. (Journal of medicinal chemistry, 2026, PMID 42275647): "New series of Pt(IV) complexes (Pt5-Pt13) bearing 1,4-naphthoquinone (NQ, a natural active skeleton) derivatives (c1-c3) as potential dual CDC25A/NF-kB inhibitory ligands were synthesized and characterized."
• Jan Protocatechuic acid prevents obesity caused by long-chain saturated fatty acid-induced inflammation in mouse microglia via inhibition of the NF-κB pathway. (PloS one, 2026, PMID 42224300): "PCA inhibited the ubiquitin-proteasome degradation of IκBα induced by LCSFAs, suppressing the nuclear translocation of NF-κB and the expression of pro-inflammatory cytokine genes, which was indicated to be attributed to the suppression of I kappa B kinase."
• May Quercetin Alleviates Postoperative Cognitive Dysfunction of Aged Mice by Regulating Microglial Polarization through Inducing miR-379-5p RNA Modification. (Molecular neurobiology, 2026, PMID 42209865): "GSK3β overexpression suppressed microglia viability and induced M1 polarization by activating NF-κB/STAT3 signal and the NLRP3 inflammasome and interacting with ed-miR-379-5p."
• May Theranekron attenuates lipopolysaccharide-induced neuroinflammation via NLRP3 inflammasome modulation. (Molecular biology reports, 2026, PMID 42189344): "...key neuroinflammatory pathways involving the NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome."
• Jul Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. (International journal of molecular medicine, 2026, PMID 42169649): "Mechanistic studies in HK‑2 cells demonstrated that Rg3 (80 µg/ml) attenuated CP‑induced NLRP3 inflammasome activation (NLRP3, apoptosis‑associated speck‑like protein with CARD (ASC), caspase‑1) and p‑p65 expression; these effects were reversed by the SIRT1 inhibitor Ex527, implicating SIRT1 pathway dependency."
• May Neuroprotective effects of trans-anethole on AlCl₃-induced memory impairment: targeting AChE, oxidative stress, and NLRP3 inflammasome: a promising approach for neurodegeneration prevention. (Metabolic brain disease, 2026, PMID 42154340): "Neuroprotective effects were evaluated by analyzing acetylcholinesterase (AChE) activity, oxidative stress markers (catalase, glutathione, and malondialdehyde levels), and neuroinflammatory mediators (NLRP3 inflammasome, Interleukin-1β, and TNF-α) in AlCl₃-exposed rats."